A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
Status:
RECRUITING
Trial end date:
2027-09-18
Target enrollment:
Participant gender:
Summary
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer.
Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
Phase:
PHASE1
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano